Lumipulse® G NfL Blood Assay
Neuroaxonal Damage (MS, ALS)
CommercialCE Marked (Mar 2026)
Key Facts
Indication
Neuroaxonal Damage (MS, ALS)
Phase
Commercial
Status
CE Marked (Mar 2026)
Company
About fujirebio-diagnostics
Fujirebio Diagnostics is an R&D-driven innovator and global provider of in vitro diagnostic solutions, with a mission to create new value in healthcare. Its core achievement is pioneering blood-based biomarkers for Alzheimer's disease, including the first FDA-cleared blood test for amyloid pathology. The company's strategy leverages its proprietary Lumipulse® G platform for internal assay development while operating a synergistic CDMO business, reinvesting partnership revenues to fuel a robust pipeline in neurology, oncology, and infectious diseases.
View full company profile